When compared to inhibitors that block only one kinase target, CKD, JAK2, or FLT3, TGO2 exhibited increased potency with significantly lower IC50 in cell assays composed of various solid and liquid tumor lines. This evidence concerns the gene JAK2 and chronic kidney disease.